AC
HOWL icon

Aristides Capital’s Werewolf Therapeutics HOWL Stock Holding History

Aristides Capital’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-25,585
Closed -$446K – 173
2021
Q2 		$446K Buy
+25,585
New +$350K 0.1% 93

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Aristides Capital's HOWL Position: Q3 2021 in Review

Aristides Capital sold out of Werewolf Therapeutics (HOWL) in Q3 2021, closing a stake of 25,585 shares — an estimated $446K sold.

Aristides Capital first reported a position in HOWL in Q2 2021 and held it in 1 quarter. The position peaked at $446K in Q2 2021. 42 funds tracked by Wall St. Rank hold HOWL as of Q3 2021.

  • Aristides Capital reported no remaining Werewolf Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Aristides Capital sold 25,585 Werewolf Therapeutics shares in Q3 2021, an estimated $446K.
  • Aristides Capital first reported a position in Werewolf Therapeutics in Q2 2021 and held it in 1 quarter.
  • Aristides Capital's Werewolf Therapeutics position peaked at $446K in Q2 2021.
  • 42 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q3 2021.

Based on Aristides Capital's 13F filing for Q3 2021, filed 12 Nov 2021.